Montelukast Evolugen (Montelukast Sodium)

Montelukast blocks cysteinyl leukotriene (CysLT1) receptors in the airways. By preventing leukotrienes D4, E4 and related compounds from binding, it reduces bronchoconstriction, mucus production, and inflammation. This receptor antagonism helps keep the airways open and diminishes allergic and exercise‑related respiratory symptoms.

The dosage of Montelukast Evolugen is determined by the prescribing healthcare professional based on the patient’s age, weight, and clinical condition. Typical adult regimens involve a once‑daily tablet, but exact strength and frequency must be confirmed by the prescriber and reflected on the prescription label.

Safety data for Montelukast during pregnancy and lactation are limited, and the product carries an unknown pregnancy category. Healthcare providers should weigh potential benefits against possible risks and discuss alternative options. Women who are pregnant, planning pregnancy, or breastfeeding should consult their physician before starting therapy.

To place an order, submit an enquiry on the Montelukast Evolugen product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or antihistamines for asthma and allergic rhinitis. Unlike inhaled steroids, it is taken once daily and does not require a device, but it may be less potent for severe asthma. Compared with other leukotriene antagonists such as zafirlukast, montelukast has a more favorable dosing schedule and broader regulatory approval.

Montelukast Evolugen tablets should be stored at room temperature, below 25 °C, in their original packaging to protect from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in bathrooms or near heat sources, and discard any tablets that appear discolored or damaged.

Montelukast Evolugen is taken orally as a tablet. Swallow the tablet whole with water; it may be taken with or without food. For consistent blood levels, it is usually recommended to take the dose at the same time each day, preferably in the evening for asthma maintenance, unless otherwise directed by a healthcare professional.

Serious adverse events include severe allergic reactions such as angioedema, skin conditions like Stevens‑Johnson syndrome, eosinophilic granulomatosis with polyangiitis, hepatic injury, and neuropsychiatric effects including mood changes, depression, or suicidal thoughts. Patients should seek immediate medical attention if they experience swelling of the face or throat, rash, jaundice, or any sudden change in mental health.

Montelukast should be avoided in individuals with known hypersensitivity to montelukast sodium or any tablet excipients. Caution is advised for patients with severe hepatic impairment, and it is not recommended for use in children under the age approved for the specific formulation without medical supervision. Pregnant or breastfeeding women should only use it after a thorough risk‑benefit discussion with their physician.